Rivaroxaban outperformed by VKAs for AF in rheumatic heart disease

Contrary to expectations, vitamin K antagonists (VKAs) reduced the risk of ischemic stroke and death compared with rivaroxaban, a factor Xa inhibitor (Xarelto, Janssen) in patients with rheumatic heart disease and atrial fibrillation, in the INVICTUS trial. Patients receiving a VKA, usually warfarin, had a 25% lower risk for the primary outcome – a composite …

Rivaroxaban outperformed by VKAs for AF in rheumatic heart disease Read More »